Functional assays revealed that NEK8 knockdown inhibited CRC cell proliferation, migration, and invasion, reinforcing its potential as a therapeutic target.<h4>Conclusions</h4>The NECSO-derived signature provides a novel prognostic tool that integrates immune evasion and metabolic reprogramming in CRC. The gene discussed is NEK8; the disease is colorectal carcinoma.